Postprandial effects of alirocumab on lipemia and inflammtio
- Conditions
- Diabetes Mellitus Type 2 (T2DM), postprandial lipemia
- Registration Number
- NL-OMON22535
- Lead Sponsor
- Franciscus Gasthuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
• Age of 18 years of older;
• Male
Exclusion Criteria
• Current smoking
• Impaired renal function (MDRD <60 ml/min/1.73 m2)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint is effect of alirocumab on postprandial leukocyte activation markers (CD11b, CD66b and CD35).
- Secondary Outcome Measures
Name Time Method Secondary endponts are the effect of 9 weeks of treatment with alirocumab on postprandial lipemia (apoB48, triglycerides, free fatty acids and b-hydroxybutyrate), oxidative stress (myeloperoxidase) and vascular function (arterial pulse wave velocity and arterial pulse wave analysis).